Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Antifungal Isavuconazole In Line For 12-Year Exclusivity: QIDP+Orphan Combos Are Rare

This article was originally published in RPM Report

Executive Summary

Astellas Pharma’s isavuconazole should soon become the first antifungal therapy approved with the added exclusivity award for Qualified Infectious Disease Products under the GAIN Act. It will also be the first product to receive both QIDP and Orphan Drug exclusivity – a combination that probably won’t happen often.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts